
ALT WOW! PRIME medicine has just announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM577a - Prime Medicine’s In Vivo Prime Editor for Wilson disease (WD). This clearance paves the way for Prime to initiate a clinical trial in the U.S and together with Prime’s previously announced New Zealand Clinical Trial Application (CTA) clearance, today’s IND clearance establishes a global Phase 1/2 program and opens participation to patients in the U.S - where H1069Q is the single most common pathogenic variant causing WD.

ALT WOW! Prime Medicine has announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has cleared its Clinical Trial Application (CTA) for $PRME PM577a - an investigational Prime Editor for Wilson Disease 🧵👇. Today’s clearance represents the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine and enables the initiation of a global Phase 1/2 study.































